Cargando…
Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
Pulmonary arterial hypertension (PAH) and novel coronavirus (SARS-CoV-2) disease COVID-19 are characterized by extensive endothelial dysfunction and inflammation leading to vascular remodeling and severe microthrombi and microvascular obliterative disease. It is hypothesized that those patients with...
Autores principales: | Franco, Veronica, Bradley, Elisa A., Badagliacca, Roberto, Sabanayagam, Aarthi, Rajpal, Saurabh, Lastinger, Lauren T., Daniels, Curt J., Smith, J. Shaun, Benza, Raymond L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686637/ https://www.ncbi.nlm.nih.gov/pubmed/33282201 http://dx.doi.org/10.1177/2045894020970369 |
Ejemplares similares
-
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
por: Elliott, C. Gregory, et al.
Publicado: (2019) -
Are anticoagulants still indicated in pulmonary arterial hypertension?
por: Olschewski, Horst, et al.
Publicado: (2018) -
The use of chromoendoscopy for surveillance of inflammatory bowel disease
por: Lichtenstein, Gary R., et al.
Publicado: (2018) -
Trade in wild animals: a disaster ignored
por: The Lancet Infectious Diseases
Publicado: (2003) -
A European CDC
por: The Lancet Infectious Diseases
Publicado: (2003)